Although data on age, stage, histopathology, and MYCN amplification can be confidently obtained in most clinical settings [24], the detection of Seg+, that accounts for 37% of NB and confers a dismal outcome [3], requires time- and resource-consuming pangenomic methods or multiple in situ hybridizations [22]. Here, MYCN is linked to neuroblastoma.